Related Experiment Videos
Cyclophosphamide-induced facial discomfort
J L Kosirog-Glowacki1, L R Bressler
1Department of Pharmacy Practice, University of Illinois at Chicago.
The Annals of Pharmacotherapy
|February 1, 1994
Summary
Cyclophosphamide can cause facial discomfort, including burning and tingling. Intranasal ipratropium bromide may help prevent these reactions, warranting further investigation for managing chemotherapy side effects.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Cyclophosphamide is a widely used chemotherapy agent.
- Facial discomfort is a potential side effect of cyclophosphamide administration.
- Previous literature on this specific side effect is limited.
Observation:
- A university teaching hospital oncology clinic reported 14 cases of cyclophosphamide-induced facial discomfort between 1990 and 1993.
- Symptoms included facial or scalp burning, oropharyngeal tingling, nasal congestion, rhinorrhea, sneezing, and lacrimation.
- These symptoms may be more common than previously recognized.
Findings:
- Interventions such as altering cyclophosphamide infusion duration or concentration provided variable improvement.
- Intranasal ipratropium bromide was investigated as a potential preventative measure.
- Variable degrees of symptom improvement were observed with intranasal ipratropium bromide.
Implications:
- Careful patient questioning is essential to identify and address cyclophosphamide-induced facial discomfort.
- Further research into intranasal ipratropium bromide and other preventative strategies is recommended.
- Improved management of chemotherapy-related side effects can enhance patient quality of life.